0000000000205445

AUTHOR

Hans-peter Sinn

showing 6 related works from this author

Synthetische Antitumor-Vakzine aus MUC1-Glycopeptiden mit zwei immundominanten Domänen - Induktion einer starken Immunreaktion gegen Brusttumorgewebe

2011

Sialyl Tn antigenChemistryGeneral MedicineMolecular biologyAngewandte Chemie
researchProduct

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

2021

Geburtshilfe und Frauenheilkunde 81(10), 1112-1120 (2021). doi:10.1055/a-1499-8431

medicine.medical_specialtyAxillary lymph nodesBreast surgerymedicine.medical_treatmentMammakarzinomBreast cancerbreast cancerMaternity and MidwiferyAdjuvant therapymedicineddc:610GebFra ScienceStage (cooking)Sentinel-Lymphknoten-Entfernungtargeted axillary dissectionsentinel LNEneoadjuvante Chemotherapiebusiness.industryObstetrics and Gynecologymedicine.diseaseRadiation therapyDissectionAxillamedicine.anatomical_structuregezielte axilläre DissektionRadiologybusinessRecommendation/Empfehlungneoadjuvant chemotherapy
researchProduct

Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.

2003

This study was undertaken to investigate the prevalence of BRCA1 and BRCA2 germline mutations in 91 German patients unselected for family history, who were diagnosed with breast cancer before the age of 41 years. Clinical information and blood samples were obtained from all patients. A comprehensive BRCA1 and BRCA2 mutational analysis was performed using the protein truncation assay and single-strand conformational polymorphism analysis followed by DNA sequencing of variant signals detected by these assays. Five different deleterious germline mutations including four frameshift mutations and one missense mutation were identified, three in BRCA1 (3.3%) and two mutations (2.2%) in BRCA2. Both…

Adultendocrine system diseasesDNA Mutational AnalysisGenes BRCA2Genes BRCA1Mutation MissenseBreast NeoplasmsDiseaseBiologyGenetic determinismDNA sequencingFrameshift mutationGermline mutationBreast cancerGermanyGeneticsmedicineMissense mutationHumansGenetic TestingFamily historyskin and connective tissue diseasesFrameshift MutationGenetics (clinical)Germ-Line MutationGeneticsmedicine.diseaseFemaleEuropean journal of human genetics : EJHG
researchProduct

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032…

2018

Geburtshilfe und Frauenheilkunde 78(11), 1056-1088 (2018). doi:10.1055/a-0646-4630

medicine.medical_specialtyAdvanced breastPsychological interventionGuideline/LeitlinieSystemic therapymetastasiertes Mammakarzinomprimary breast cancer03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerMaternity and MidwiferyBrustkrebsMedicineprimäres Mammakarzinom030212 general & internal medicineGebFra ScienceIntensive care medicineLeitlinietherapybusiness.industryTumor biologyObstetrics and GynecologyCancerGuidelinemedicine.diseaseMetastatic breast cancerddc:030220 oncology & carcinogenesismetastatic breast cancerbusinessTherapieguideline
researchProduct

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032…

2018

62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, DGGG'18, Berlin, Germany, 31 Oct 2018 - 3 Nov 2018; Geburtshilfe und Frauenheilkunde 78(10), 927-948 (2018). doi:10.1055/a-0646-4522 special issue: "62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, DGGG'18, Berlin, 31.10 – 03.11.2018 : Frauenheilkunde im Fokus: wissenschaftlich fundiert und der Qualität verpflichtet"

medicine.medical_specialtydiagnosisPsychological interventionComputed tomographyDiseaseGuideline/LeitlinieMammakarzinom03 medical and health sciencesbreast cancerDiagnostik0302 clinical medicineBreast cancerMaternity and Midwiferyfollow-upmedicineMammographyMedical physicsGebFra Science030212 general & internal medicinemedicine.diagnostic_testbusiness.industryscreeningObstetrics and GynecologyCancerGuidelinemedicine.diseaseddc:030220 oncology & carcinogenesisFrüherkennungRichtlinieNachsorgebusinessguidelineSystematic searchGeburtshilfe und Frauenheilkunde
researchProduct

Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor…

2011

A shot in the arm for cancer treatment: two MUC1 tetanus toxoid vaccines were synthesized and induced a strong immune response in mice. The antibodies elicited by the vaccines show a high selectivity for the tumor cells in mammary carcinoma tissues and also distinguish between tumor tissues at different stages.

Molecular ConformationAntineoplastic AgentsBreast Neoplasmscomplex mixturesCancer VaccinesCatalysisBreast tumorMiceImmune systemmedicineAnimalsMUC1Mice Inbred BALB CVaccines SyntheticbiologyTetanusChemistryMucin-1ToxoidGlycopeptidesMammary Neoplasms ExperimentalGeneral Chemistrymedicine.diseaseGlycopeptideCancer researchbiology.proteinMCF-7 CellsExperimental pathologyFemaleAntibodyDrug Screening Assays AntitumorAngewandte Chemie (International ed. in English)
researchProduct